Zihel Hussein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zihel Hussein has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hanaa Al-Mahmoodi
College of Biotechnology, Al-Nahrain University, Baghdad, Iraq .
1 shared publication - Hazhmat Ali
College of Medicine, University of Duhok, Duhok, 42001, Kurdistan Region, Iraq
1 shared publication - Hishyar Azo Najeeb
College of Medicine, University of Duhok, Duhok, Iraq.
1 shared publication - Mayada Yalda
College of Medicine, University of Duhok, Duhok, Iraq.
1 shared publication - Qais Al Ismaeel
College of Medicine, University of Duhok, Duhok, Iraq.
1 shared publication - Shelan Rasool
Department of Anatomy, Biology, and Histology, College of Medicine, University of Duhok, Duhok, 42001, Iraq
1 shared publication
Latest Publications
- Open Access
- 2 August 2025
- Published by University of Kufa in Al-Kufa University Journal for Biology
- Vol. 17 (2) , 18-25
Methylation Status of the RB1 Gene as a Diagnostic and Prognostic Tool in Breast Cancer: Correlations with Clinicopathological Features and Immunohistochemical Markers
Background The RB1 gene plays important role in regulating the cell cycle and has been implicated in various malignancies, including breast cancer. Methylation-specific PCR (MSP) was used to assess RB1 methylation, while immunohistochemical markers such as ER, PR, HER2, and Ki-67 were analyzed to correlate molecular changes with clinical characteristics. The findings demonstrate that aberrant RB1methylation is significantly linked to more aggressive tumor phenotypes, including higher histologic grade, advanced stage, and elevated Ki-67 expression. Furthermore, RB1 methylation status correlated with poor survival outcomes, suggesting its role as a prognostic biomarker. This study underscores the importance of RB1 methylation in breast cancer pathophysiology and its potential clinical utility. Method A total of 40 primary breast carcinoma tissue samples and 10 non-neoplastic breast tissue samples were collected from the pathology archives of medical institutions in Duhok, Iraq. Clinical and pathological data, including patient age, tumor size, stage, and grade, were retrieved from medical records. Hematoxylin and Eosin (H&E) staining was performed to confirm diagnosis. Immunohistochemical (IHC) staining was conducted for Ki-67, ER, PR, and HER2, while MSP was employed to evaluate RB1 methylation and its association with clinical parameters. Results All patients in this study were female, with 70% being over 50 years old. Immunohistochemical analysis revealed that ER, PR, and HER2 were negative in 65%, 70%, and 60% of cases, respectively, while 70% of tumors exhibited high Ki-67 expression. A significant correlation was found between Ki-67 expression and receptor status, as well as other clinicopathological features. RB1 methylation was identified in 24 cases (60%), demonstrating a strong association with tumor aggressiveness and immunohistochemical markers. Conclusion The study confirms the association between RB1 methylation and breast cancer progression. Evaluating RB1 methylation status could provide valuable diagnostic and prognostic insights, potentially guiding targeted therapeutic strategies.
- 2 August 2025
- Published by University of Kufa in Al-Kufa University Journal for Biology
- Vol. 17 (2) , 18-25
Open AccessMethylation Status of the RB1 Gene as a Diagnostic and Prognostic Tool in Breast Cancer: Correlations with Clinicopathological Features and Immunohistochemical Markers
Background The RB1 gene plays important role in regulating the cell cycle and has been implicated in various malignancies, including breast cancer. Methylation-specific PCR (MSP) was used to assess RB1 methylation, while immunohistochemical markers such as ER, PR, HER2, and Ki-67 were analyzed to correlate molecular changes with clinical characteristics. The findings demonstrate that aberrant RB1methylation is significantly linked to more aggressive tumor phenotypes, including higher histologic grade, advanced stage, and elevated Ki-67 expression. Furthermore, RB1 methylation status correlated with poor survival outcomes, suggesting its role as a prognostic biomarker. This study underscores the importance of RB1 methylation in breast cancer pathophysiology and its potential clinical utility. Method A total of 40 primary breast carcinoma tissue samples and 10 non-neoplastic breast tissue samples were collected from the pathology archives of medical institutions in Duhok, Iraq. Clinical and pathological data, including patient age, tumor size, stage, and grade, were retrieved from medical records. Hematoxylin and Eosin (H&E) staining was performed to confirm diagnosis. Immunohistochemical (IHC) staining was conducted for Ki-67, ER, PR, and HER2, while MSP was employed to evaluate RB1 methylation and its association with clinical parameters. Results All patients in this study were female, with 70% being over 50 years old. Immunohistochemical analysis revealed that ER, PR, and HER2 were negative in 65%, 70%, and 60% of cases, respectively, while 70% of tumors exhibited high Ki-67 expression. A significant correlation was found between Ki-67 expression and receptor status, as well as other clinicopathological features. RB1 methylation was identified in 24 cases (60%), demonstrating a strong association with tumor aggressiveness and immunohistochemical markers. Conclusion The study confirms the association between RB1 methylation and breast cancer progression. Evaluating RB1 methylation status could provide valuable diagnostic and prognostic insights, potentially guiding targeted therapeutic strategies.
- Open Access
- 27 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (11) , 134-143
The emerging role of S100A4 and S100A14 proteins in colorectal cancer progression
Colorectal cancer (CRC) is the third most frequent type of cancer and the second leading cause of cancer-related deaths globally. Despite a thorough understanding of its biology, etiology, and epidemiology, an estimated 1.8 million new cases are diagnosed each year, and 900000 people die as a result of malignancy. The current study aims to investigate the expression pattern of S100A4 and S100A14 proteins in CRC tissue specimens and a panel of cell lines. Furthermore, to explore the metastatic potential of the aforementioned proteins in relation to the epithelial-mesenchymal transition and their possible association with the clinical features of CRC. The present study involved 80 patients diagnosed with CRC. Upon identification of the sociodemographic and clinicopathological features of the participants, immunohistochemical studies were conducted to measure the expression pattern of the S100 proteins in CRC tissues. In addition to qPCR and western blot studies, a series of in vitro experiments were conducted in a panel of CRC cell lines to assess the effects of S100 protein expression in cell migration, invasion, and proliferation. The number of CRC patients with high S100A4 expression levels was considerably higher than those with low expression (p In vitro studies demonstrated that S100A14 knockdown induced EMT and resulted in a substantial increase in cell proliferation, migration, and invasion in HT29 cells. Moreover, S100A4 knockdown substantially inhibited migration, invasion, and proliferation in LoVo cells. The findings collectively suggest that both S100A4 and S100A14 play a pivotal role in colorectal cancer progression. Overexpression of S100A4 consistently with S100A14 downregulation is associated with the activation of epithelial-mesenchymal transition, which in turn enhances cell proliferation, migration, and invasion.
- 27 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (11) , 134-143
Open AccessThe emerging role of S100A4 and S100A14 proteins in colorectal cancer progression
Colorectal cancer (CRC) is the third most frequent type of cancer and the second leading cause of cancer-related deaths globally. Despite a thorough understanding of its biology, etiology, and epidemiology, an estimated 1.8 million new cases are diagnosed each year, and 900000 people die as a result of malignancy. The current study aims to investigate the expression pattern of S100A4 and S100A14 proteins in CRC tissue specimens and a panel of cell lines. Furthermore, to explore the metastatic potential of the aforementioned proteins in relation to the epithelial-mesenchymal transition and their possible association with the clinical features of CRC. The present study involved 80 patients diagnosed with CRC. Upon identification of the sociodemographic and clinicopathological features of the participants, immunohistochemical studies were conducted to measure the expression pattern of the S100 proteins in CRC tissues. In addition to qPCR and western blot studies, a series of in vitro experiments were conducted in a panel of CRC cell lines to assess the effects of S100 protein expression in cell migration, invasion, and proliferation. The number of CRC patients with high S100A4 expression levels was considerably higher than those with low expression (p In vitro studies demonstrated that S100A14 knockdown induced EMT and resulted in a substantial increase in cell proliferation, migration, and invasion in HT29 cells. Moreover, S100A4 knockdown substantially inhibited migration, invasion, and proliferation in LoVo cells. The findings collectively suggest that both S100A4 and S100A14 play a pivotal role in colorectal cancer progression. Overexpression of S100A4 consistently with S100A14 downregulation is associated with the activation of epithelial-mesenchymal transition, which in turn enhances cell proliferation, migration, and invasion.